iBio (IBIO) Liabilities and Shareholders Equity (2011 - 2026)

iBio (IBIO) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $85.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 349.32% year-over-year to $85.8 million; the TTM figure through Mar 2026 stood at $237.6 million (up 152.59% YoY), while the FY2025 annual figure was $23.2 million, down 19.31% from the prior year.
• Liabilities and Shareholders Equity grew to $85.8 million in Q1 2026 per IBIO's latest filing, from $64.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $115.4 million in Q1 2022 and bottomed at $19.1 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $52.4 million across 5 years, with a median of $44.4 million in 2023.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity slumped 61.91% — and 2026, when it jumped 349.32%.
• iBio's Liabilities and Shareholders Equity stood at $51.8 million in 2022, then plunged by 34.32% to $34.0 million in 2023, then sank by 36.23% to $21.7 million in 2024, then jumped by 196.78% to $64.4 million in 2025, then surged by 33.3% to $85.8 million in 2026.
• Business Quant data shows IBIO's Liabilities and Shareholders Equity at $85.8 million in Q1 2026, $64.4 million in Q4 2025, and $64.2 million in Q3 2025.